Recent Research Analysts’ Ratings Updates for T2 Biosystems (TTOO)

T2 Biosystems (NASDAQ: TTOO) has recently received a number of price target changes and ratings updates:

  • 3/21/2017 – T2 Biosystems was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. “
  • 3/15/2017 – T2 Biosystems was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. “
  • 3/14/2017 – T2 Biosystems was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $5.00 price target on the stock.
  • 3/8/2017 – T2 Biosystems was given a new $7.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/14/2017 – T2 Biosystems was given a new $7.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/14/2017 – T2 Biosystems was given a new $9.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 2/5/2017 – T2 Biosystems had its “buy” rating reaffirmed by analysts at WBB Securities. They now have a $12.00 price target on the stock. They wrote, “We Believe that in the not too distant future, doctors in residency will be trained to detect fungal and bacterial infections in hours with 95% accuracy versus the current blood culture standard of two days on average for invasive candidiasis detection, with 38% accuracy. This is the special province that T2 Biosystems, Inc. (TTOO) presently dominates. We are therefore reiterating our Strong Buy Rating and 12-Month Price Target of $12.00.””

Shares of T2 Biosystems Inc (NASDAQ:TTOO) traded up 4.92% during mid-day trading on Monday, reaching $5.54. The company had a trading volume of 50,349 shares. The stock’s market capitalization is $169.39 million. The company’s 50-day moving average is $5.82 and its 200 day moving average is $6.06. T2 Biosystems Inc has a 52-week low of $4.89 and a 52-week high of $11.30.

In other T2 Biosystems news, Director David B. Elsbree purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, March 15th. The shares were purchased at an average price of $5.97 per share, for a total transaction of $59,700.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $238,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 43.20% of the company’s stock.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

5 Day Chart for NASDAQ:TTOO

Receive News & Ratings for T2 Biosystems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.